A Warning About GLP-1 Drugs
Juanita Gantt, a 62-year-old woman struggling with weight and diabetes, was prescribed Wegovy and later Ozempic, both GLP-1 drugs manufactured by Novo Nordisk. Initially, she felt positive about the medications, experiencing reduced appetite and cravings. However, her life took a drastic turn in October 2023 when she was found unconscious by her husband.
Doctors discovered parts of her large intestine had died and needed removal. During her recovery, she suffered cardiac arrest, leaving her daughter fearing for her life. The surgery resulted in a permanent ileostomy bag attached to her abdomen for waste collection.
Gantt claims she was never warned about the potential side effects of these medications, including gastroparesis, bowel obstruction, and the possibility of severe complications. She is now suing Novo Nordisk, alleging that the company's drug labels do not adequately inform patients and doctors about these risks.
Novo Nordisk maintains that the known risks and benefits of their GLP-1 drugs are clearly outlined in the FDA-approved product labeling. They claim the allegations in the lawsuit are without merit and intend to vigorously defend themselves.
This incident highlights the importance of careful consideration when using prescription medications, even those considered "game changers" like GLP-1 drugs. While these medications can offer significant benefits for weight loss and diabetes management, patients must be aware of the potential risks.
A study published in October 2023 found a higher risk of bowel obstruction and stomach paralysis associated with certain GLP-1 drugs compared to other weight loss medications. While these complications are relatively rare, it's crucial for patients to understand their individual risk and weigh it against the potential benefits.
Juanita Gantt's story serves as a cautionary tale, urging patients to be informed about the potential side effects of any medication they take and to discuss any concerns with their healthcare provider.